Immunocompromised Americans who are not adequately protected by their Covid-19 vaccination series will now have an additional option for long-term protection in the form of an antibody cocktail drug developed by AstraZeneca.
FDA Approves Anti-SARS-CoV-2 Monoclonal Antibodies For The Vaccine Insensitive Immune Suppressed Population
